AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$DNA

HENRY CHRISTIAN O sold $35K of DNA

HENRY CHRISTIAN O sold 5,000 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $7.08 on 2026-09-15.

Original reporting
SEC EDGAR · HENRY CHRISTIAN O
Published Sep 16, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DNA
Neutral
high confidence
Mentioned
$DNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNANeutralLow
01

Why it matters

The director's sale is routine and unlikely to affect market perception of Ginkgo Bioworks.

02

Market read

Low relevance; the filing provides a factual update but no actionable trading signal.

03

What to watch

Potential upcoming dilution from future financing rounds.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$DNANeutralHigh confidence
Context

Director Henry Christian O sold 5,000 shares for $35,405 on Sep 15, 2026.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

The transaction size is small relative to float and recent price, and no other catalyst is present.

Market effects

Sector

None; the sale does not affect the synthetic biology sector broadly.

Regional

None; limited to US investors.

Global

None

Counterpoint

What could challenge this read

The sale could signal insider concern, but size is too small to be meaningful.

Key entities

  • Company
    Ginkgo Bioworks Holdings, Inc.

    Synthetic biology company listed on NASDAQ under ticker DNA.

  • Insider
    Henry Christian O

    Director of Ginkgo Bioworks who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DNA insider trading history →

Related articles

$DNAMed

Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors

Ginkgo Bioworks (NYSE:DNA) reported a strategic shift toward commercializing autonomous lab hardware and cloud services during its Q3 2026 earnings call. Key points include selling hardware to biopharma partners, restructuring to reduce cash burn, and AI-driven demand for lab data. The company ended the quarter with $285M in cash and no debt. Novo Nordisk is a notable partner.

finance.yahoo.com
$DNAMed

Ginkgo Bioworks (DNA) Q3 2026 Earnings Call Transcript

Ginkgo Bioworks (DNA) reported Q3 2026 earnings, showing a 44% improvement in net loss from continuing operations to $41M and a 58% improvement in adjusted EBITDA to -$22M. Revenue was $28M, down 6% YoY. The company highlighted cost-cutting efforts, reduced cash burn, and investments in autonomous labs. They ended the quarter with $285M in cash and reaffirmed full-year cash burn guidance of $125M-$150M.

finance.yahoo.com
$DNALow

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform:

SEC EDGAR 8-K
$DNAMed

A GT investigation examines the funding, government ties and questionable business practices of seven US entities subject to China’s countermeasures

China’s Ministry of Commerce announced countermeasures against seven US entities, including Applied DNA Sciences (now BNB Plus Corp), Stratum Reservoir, Altana Technologies, Responsible Business Alliance, Verite Group, Human Rights in China, and Compliance Testing LLC, citing US sanctions over alleged forced labor in Xinjiang. The article links their roles to cotton traceability testing, AI supply-chain mapping, compliance services, and related government contracts.

globaltimes.cn
$DNAMed

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

yahoo.com